Compare
Capricor Therapeutics, Inc. vs Abbott Laboratories vs Bristol Myers Squibb Co vs Eli Lilly & Co
| Latest fiscal year | Capricor Therapeutics, Inc. CAPR | Abbott Laboratories ABT | Bristol Myers Squibb Co BMY | Eli Lilly & Co LLY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $44.33B | $48.19B | $65.18B |
| Revenue growth (YoY) | -100.0% | +5.7% | -0.2% | +44.7% |
| Gross margin | n/a | 56.4% (computed) | n/a | 83.0% (computed) |
| Operating margin | n/a | 18.2% | n/a | n/a |
| Net margin | n/a | 14.7% | 14.6% | 31.7% |
| Net income | -$105.04M | $6.52B | $7.05B | $20.64B |
| EPS (Diluted) | -$2.26 | $3.72 | $3.46 | $22.95 |
| Operating cash flow | -$69.81M | $9.57B | $14.16B | $16.81B |
| Free cash flow | -$72.72M | $7.39B | $12.85B | n/a |
| Cash & equivalents | $287.85M | $8.52B | $10.21B | $7.27B |
| Total assets | $355.95M | $86.71B | $90.04B | $112.48B |
| Total liabilities | $50.16M | n/a | $71.53B | n/a |
| Shareholders' equity | $305.79M | $52.13B | $18.47B | $26.54B |
| Return on year-end equity | -34.4% | 12.5% | 38.2% | 77.8% |
| Shares outstanding | 57.37M | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Capricor Therapeutics, Inc. | Abbott Laboratories | Bristol Myers Squibb Co | Eli Lilly & Co |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $44.33B Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $65.18B Ended 2025-12-31 |
| 1 year earlier | $22.27M Ended 2024-12-31 | $41.95B Ended 2024-12-31 | $48.30B Ended 2024-12-31 | $45.04B Ended 2024-12-31 |
| 2 years earlier | $25.18M Ended 2023-12-31 | $40.11B Ended 2023-12-31 | $45.01B Ended 2023-12-31 | $34.12B Ended 2023-12-31 |
| 3 years earlier | $2.55M Ended 2022-12-31 | $43.65B Ended 2022-12-31 | $46.16B Ended 2022-12-31 | $28.54B Ended 2022-12-31 |
| 4 years earlier | $244.9K Ended 2021-12-31 | $43.08B Ended 2021-12-31 | $46.38B Ended 2021-12-31 | $28.32B Ended 2021-12-31 |